Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

被引:0
|
作者
Wang, Yan [1 ,2 ]
Li, Fangyu [1 ,2 ]
Qin, Qi [1 ,2 ]
Li, Tingting [1 ,2 ]
Wang, Qi [1 ,2 ]
Li, Yan [1 ,2 ]
Li, Ying [1 ,2 ]
Jia, Jianping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
[3] Capital Med Univ, Clin Ctr Neurodegenerat Dis & Memory Impairment, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Collaborat Innovat Ctr Brain Disorders, Beijing, Peoples R China
[5] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
来源
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE | 2025年 / 12卷 / 04期
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Biomarker; Cognitive decline; CEREBROSPINAL-FLUID; TAU; METAANALYSIS; LOCI; BETA;
D O I
10.1016/j.tjpad.2025.100065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Apolipoprotein E epsilon 4 (APOE epsilon 4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE epsilon 4, which has guiding significance for the clinical practical application. Methods: The differences in CSF biomarkers and their performances between APOE epsilon 4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed. The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE epsilon 4 carriers and non-carriers, as well as the critical values corresponding Youden Index. Results: In a cross sectional convenience sample of 1610 participants, lower A beta 42 and A beta 42/A beta 40 and higher p-Tau 181/A beta 42 in CSF were observed among APOE epsilon 4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05). The performance of CSF p-tau/A beta 42 in distinguishing MCI from NC among APOE epsilon 4 carriers was superior to non-carriers [AUC: 0.714 (95%CI: 0.673- 0.752) vs 0.600 (95%CI: 0.564- 0.634), P< 0.001], although it was similar in distinguishing AD from NC between APOE epsilon 4 carriers and non-carriers [AUC: 0.874 (95%CI: 0.835-0.906) vs 0.876 (95%CI: 0.843- 0.904)]. In the longitudinal cohort of 254 participants, the association of CSF A beta 42, A beta 42/A beta 40 and p-Tau181/A beta 42 with cognitive decline were stronger in APOE epsilon 4 carriers compared to non-carriers (P< 0.05). Meanwhile, the critical values were different depending on APOE genotype. Discussion: The CSF level of p-Tau181/A beta 42 was significantly different between APOE epsilon 4 carriers and non-carriers at different stages of AD. The results indicate that the performances of CSF biomarkers are influenced by APOE epsilon 4, which should be considered in the practical application.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease
    Delvenne, Aurore
    Gobom, Johan
    Schindler, Suzanne E.
    ten Kate, Mara
    Reus, Lianne M.
    Dobricic, Valerija
    Tijms, Betty M.
    Benzinger, Tammie L. S.
    Cruchaga, Carlos
    Teunissen, Charlotte E.
    Ramakers, Inez
    Martinez-Lage, Pablo
    Tainta, Mikel
    Vandenberghe, Rik
    Schaeverbeke, Jolien
    Engelborghs, Sebastiaan
    De Roeck, Ellen
    Popp, Julius
    Peyratout, Gwendoline
    Tsolaki, Magda
    Freund-Levi, Yvonne
    Lovestone, Simon
    Streffer, Johannes
    Barkhof, Frederik
    Bertram, Lars
    Blennow, Kaj
    Zetterberg, Henrik
    Visser, Pieter Jelle
    Vos, Stephanie J. B.
    ALZHEIMERS & DEMENTIA, 2024, 20 (09) : 6205 - 6220
  • [32] Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease
    Parnetti, Lucilla
    Chiasserini, Davide
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 479 - 484
  • [33] APOE ε4-associated heterogeneity of neuroimaging biomarkers across the Alzheimer's disease continuum
    Mares, Jason
    Kumar, Gautam
    Sharma, Anurag
    Emrani, Sheina
    Mcintire, Laura Beth
    Guo, Jia
    Menon, Vilas
    Nuriel, Tal
    ALZHEIMERS & DEMENTIA, 2025, 21 (01)
  • [34] Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype
    Mofrad, Rosha Babapour
    Tijms, Betty M.
    Scheltens, Philip
    Barkhof, Frederik
    van der Flier, Wiesje M.
    Sikkes, Sietske A. M.
    Teunissen, Charlotte E.
    NEUROLOGY, 2020, 95 (17) : E2378 - E2388
  • [35] Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease
    Geijselaers, Stefan L. C.
    Aalten, Pauline
    Ramakers, Inez H. G. B.
    De Deyn, Peter Paul
    Heijboer, Annemieke C.
    Koek, Huiberdina L.
    OldeRikkert, Marcel G. M.
    Papma, Janne M.
    Reesink, Fransje E.
    Smits, Lieke L.
    Stehouwer, Coen D. A.
    Teunissen, Charlotte E.
    Verhey, Frans R. J.
    van der Flier, Wiesje M.
    Biessels, Geert Jan
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 61 (01) : 309 - 320
  • [36] Use of CSF biomarkers in Alzheimer’s disease clinical trials
    K. Blennow
    H. Zetterberg
    JNHA - The Journal of Nutrition, Health and Aging, 2009, 13
  • [37] Age and diagnostic performance of Alzheimer disease CSF biomarkers
    Mattsson, N.
    Rosen, E.
    Hansson, O.
    Andreasen, N.
    Parnetti, L.
    Jonsson, M.
    Herukka, S. -K.
    van der Flier, W. M.
    Blankenstein, M. A.
    Ewers, M.
    Rich, K.
    Kaiser, E.
    Verbeek, M. M.
    Rikkert, M. Olde
    Tsolaki, M.
    Mulugeta, E.
    Aarsland, D.
    Visser, P. J.
    Schroeder, J.
    Marcusson, J.
    de Leon, M.
    Hampel, H.
    Scheltens, P.
    Wallin, A.
    Eriksdotter-Jonhagen, M.
    Minthon, L.
    Winblad, B.
    Blennow, K.
    Zetterberg, H.
    NEUROLOGY, 2012, 78 (07) : 468 - 476
  • [38] Use of CSF biomarkers in Alzheimer's disease clinical trials
    Blennow, K.
    Zetterberg, H.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (04) : 358 - 361
  • [39] Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
    Bouwman, Femke H.
    Frisoni, Giovanni B.
    Johnson, Sterling C.
    Chen, Xiaochun
    Engelborghs, Sebastiaan
    Ikeuchi, Takeshi
    Paquet, Claire
    Ritchie, Craig
    Bozeat, Sasha
    Quevenco, Frances-Catherine
    Teunissen, Charlotte
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2022, 14 (01)
  • [40] The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort
    Caroli, A.
    Frisoni, G. B.
    NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1263 - 1274